Good for the Senators who worked to sideline S. 3 this afternoon, helping to preserve a private sector component of the prescription drug coverage under Medicare. By a vote of 55-42 (3 absent), the Senate failed to invoke cloture on the Medicare Prescription Drug Price Negotiation Act (Roll Call No. 132).
As noted in the post immediately below, opponents could point to the successes of the current Medicare prescription drug plan to argue against a vast government expansion into the pharmaceutical industry. From the AP:
“Why do supporters of this legislation hate the Medicare drug benefit so much? They hate it because nothing could be more damaging to the idea of government run health care than Part D,” said Sen. Charles Grassley, R-Iowa.
No doubt we’ll see this legislation again, but with the pro-market Senators hanging tough and the President’s veto assured, moving on would seem the better course of action.
Latest posts by NAM (see all)
- Manufacturers Win Several Website Design Awards - June 15, 2011
- China Makes Commitments on Trade, Intellectual Property - December 16, 2010
- ITC Details Widespread Theft of Intellectual Property in China - December 14, 2010